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Genomic instability is one of the hall-
marks of cancer, and alterations in
DNA damage response genes have
been associated with sensitivity to
immuno-oncology modulators (Mouw
et al., 2017). Cutaneous malignant
melanoma (CMM) is the cancer with
the highest median tumor mutation
burden (Alexandrov et al., 2013). Tu-
mor mutation burden and DNA dam-
age response have been demonstrated
to have an impact on disease progres-
sion and therapy efficacy in CMM.
Immunotherapies with immune
checkpoint inhibitors (ICIs), such as
anti-PD1 and anti-CTLA4 antibodies as
well as MAPK pathway inhibitors
(MAPKis), targeting BRAF V600 mutant
and MEK proteins have significantly
improved clinical outcome for patients
with CMM. However, multiple clinical
trials conducted over the past 5 years
indicate that only a subset of patients
with CMM have long-term clinical
benefit from these therapies (Robert
et al., 2019; Topalian et al., 2019).
Loss of DNA mismatch repair causes
microsatellite instability, which is
associated with response to ICI (Le
et al., 2015). PMS2, the dimerization
partner of MLH1 and integral to
mismatch repair, has recently been
shown to carry promoter mutations in
approximately 10% of melanoma
cases, which were associated with
more than five-fold higher tumor mu-
tation burden compared with tumors
with wild-type PMS2 (Chalmers et al.,
2017).
mutT was first identified in bacteria,
and the MutT homolog (MTH1) in
humans, encoded by the NUDT1 gene,
is also a DNA repair protein andAbbreviations: CMM, cutaneous malignant melanom
MAPK pathway inhibitor; PRE, pretreatment
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oxoguanine into DNA. It is often over-
expressed in various types of cancer,
including CMM (Wang et al., 2018).
We recently reported that combining
the MTH1 inhibitor TH1579 with a
BRAF inhibitor further augments cell
death in BRAFV600 mutant CMM cells
compared with either inhibitor alone
(Das et al., 2020).
To investigate if the preclinical link
between MTH1 and mismatch repair is
also clinically relevant, we determined
the significance of MTH1 and PMS2 for
clinical outcome. We investigated the
association of their expression with
disease stage and treatment response
for ICI and MAPKi using clinical sam-
ples from CMM tumors (stages IeIV).
This study has been approved by the
Regional Ethics Committee in Stock-
holm, Sweden and has been conducted
in accordance with the ethical princi-
ples given in the Helsinki Declaration.
Written informed consent was obtained
from all patients.
The PMS2 and MTH1/NUDT1 genes
are closely localized on chromosome 7
(7p22.1 and 7p22.3, respectively). The
Cancer Genome Atlas analysis high-
lighted that when sample sets were
parsed into PMS2 and MTH1 amplifi-
cations and deletions, they significantly
co-occurred (P < 0.05) (Figure 1a). Al-
terations were significantly associated
with shorter disease-free survival (P ¼
0.03) and overall survival (P ¼ 0.001)
(Supplementary Figure S1). Gain of
chromosome 7 has been shown to be a
more frequent event in metastatic CMM
cases versus primary tumors and has
been associated with worse outcome
(Bastian et al., 1998) and resistance to
MAPKi (Villanueva et al., 2013).a; ICI, immune checkpoint inhibitor; MAPKi,
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survival was also observed in the The
Cancer Genome Atlas patient cohort
with altered MTH1 and PMS2 mRNA
expression (Figure 1b). Furthermore, a
correlation between PMS2 and MTH1
mRNA expression in the The Cancer
Genome Atlas data (P < 0.0001) was
observed (Figure 1c). This was
confirmed in our CMM stage IV cohort
by extracting data from previous
ampliSEQ analyses (Azimi et al., 2017;
Svedman et al., 2019) (P ¼ 0.0093) and
by qPCR analyses (Supplementary
Table S1) on a separate validation
cohort (P ¼ 0.0028) (Figure 1d and e).
To investigate the clinical relevance
of PMS2 and MTH1, we assessed the
protein levels using coimmuno-
fluorescence in 61 stage IeIV CMM
tumors and 5 normal skin/cancer-
adjacent skin tissue (Supplementary
Table S2). Eight samples were not
evaluable owing to excessive necrotic
areas. Compared with stage IIIeIV,
fewer stage IeII tumors and no normal
skin/adjacent tissue had high expres-
sion of MTH1 (9/31 [29%], 1/22 [5%],
and 0/5 [0%], respectively) (Figure 1f
and Supplementary Tables S2 and S3),
whereas no difference was observed
regarding cytoplasmic staining. MTH1
nuclear expression together with nu-
clear PMS2 expression was only
detected in 17 of 31 (55%) stage III/IV
but not in earlier stages (Figure 1f and
Supplementary Tables S2 and S3),
indicating an increased coexpression in
advanced disease.
Pretreatment (PRE) metastatic tumors
from a subset of the patients with CMM
with advanced disease (n ¼ 14)
receiving ICI or MAPKi therapies were
stained for both MTH1 and PMS2
(Supplementary Table S2). Of 14 cases
having moderate/high MTH1 expres-
sion together with PMS2 expression, 5
were associated with a short progres-
sion free survival (Figure 1g). Paired
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Figure 1. Coexpression at the protein level is observed in advanced stages of CMM and after disease progression to therapy. (a) TCGA data show a correlation
between PMS2 andMTH1 deletions and amplifications. (b) AlteredMTH1 and PMS2mRNA expression is associated with shorter DFS and OS. (c) TCGA mRNA
data shows a correlation between PMS2 and MTH1. (d) MTH1 and PMS2 mRNA correlated in our stage IV cohort and (e) in an independent cohort. (f)
Coexpression of MTH1 (green) and PMS2 (red) proteins is shown in stages III/IV (Bar ¼ 50 mm). (g) Survival analysis showing that moderate to high MTH1
expression together with PMS2 expression is associated with shorter PFS. (h) Induced protein expression of MTH1 and PMS2 was observed at progression after
MAPKi or ICI therapy (Bar ¼ 50 mm). CMM, cutaneous malignant melanoma; DFS, disease-free survival; ICI, immune checkpoint inhibitor; MAPKi, MAPK
pathway inhibitor; OS, overall survival; PFS, progression free survival; TCGA, The Cancer Genome Atlas.
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Figure 2. TH579 is an effective treatment option for CMM, including ICI-resistant tumor cells. (a) Induced apoptosis on cosilencing of MTH1 and PMS2 when
compared with silencing MTH1 or PMS2 alone (Student’s t-test, n ¼ 3). (b) Downregulation of PMS2 and upregulation of p-H2AX in CMM cells after 24-h
treatment with 1 mM TH1579 (n ¼ 2). (c) Reduced cell viability after 72-h treatment with TH1579 on spheroids generated using patient-derived short-term cell
lines (ANOVA test, n¼ 3) and (d) reduction in tumor spheroid sizes (ANOVA test, n¼ 3). (e) % Reduction in sphere area when comparing treatment with DMSO
control (Students t-test, n ¼ 3). (f) Increased apoptosis in patient-derived short-term cell lines after 48-h treatment with 1 mM TH1579. (g) Quantification of (f)
(Student’s t-test, n ¼ 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 3D, three-dimensional; CMM, cutaneous malignant melanoma; h, hour; ICI,
immune checkpoint inhibitor; p-H2AX, phosphorylated H2AX; PI, propidium iodide; PRE, pretreatment; PROG, progression; siCombo, Combo small interfering
RNA; siControl, control small interfering RNA; siMTH1, MTH1 small interfering RNA; siPMS2, PMS2 small interfering RNA.
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start and after progression from the
same tumor/localization in patients
receiving ICI or MAPKi (Supplementary
Table S2) demonstrated upregulation of
MTH1 and PMS2 expression levels after
disease progression in all cases
(Figure 1h).
Additionally, we investigated the ef-
fects of cosilencing MTH1 and PMS2
(Supplementary Table S4) using two
patient-derived short-term cell lines
(Supplementary Table S5), 130-PRE and
150-PRE, obtained from patients before
receiving ICI. Our analysis revealed
that an increased induction of apoptosis
with cosilencing MTH1 and PMS2
(~45e55%), compared with silencing
either gene alone (20%), was significant
(P < 0.01) in 130-PRE but did not reach
significance (P ¼ 0.07) in 150-PRE
(Figure 2a).
We and others have shown that the
MTH1 inhibitor TH1579 is a potent
drug for a wide range of cancers,
including CMM (Einarsdottir et al.,
2018). We investigated and found that
TH1579 also reduces the expression of
PMS2 in CMM cell lines (Figure 2b and
Supplementary Figure S2). We further
demonstrated that the treatment caused
elevated phosphorylated H2AX, a
marker of DNA damage, in 150-PRE
(Figure 2b and Supplementary
Figure S2). To confirm the potency of
TH1579 in a panel of patient-derived
short-term cells sensitive or resistant to
ICI (Supplementary Table S5), a
spheroid model was employed, in
which cells were treated with TH1579
for 72 hours. All cell lines showed
reduced viability (40e99%) (Figure 2c)
and reduction of tumor spheroid area
by TH1579, including a cell line (172-
progression) established from a patient
who progressed on ICI (P < 0.05)
(Figure 2d and e). We validated and
found that a reduction in cell viability
after TH1579 treatment is due to a sig-
nificant induction of cell death in 130-
PRE and 150-PRE (~35e55%, P <
0.0001) (Figure 2f and g).
Herein, we propose that TH1579
could be a good complement to ICI or
MAPKi therapy, particularly in non-
responding patient cohorts. TH1579
also downregulated PMS2 and induced
cytotoxicity in both ICI-sensitive and
-resistant CMM patient-derived short-
term cultures. Our experimental evi-
dence highlights that treatment of CMMJournal of Investigative Dermatology (2021), Volumcells with TH1579 or, alternatively,
concomitant silencing of MTH1 and
PMS2 invokes a higher induction of cell
death. A limitation of this study is the
small sample set; further follow-up
studies with larger patient cohorts are
therefore warranted to validate this hy-
pothesis and hopefully implement it
into clinical practice.
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ples, Veronica Höiom for analyzing ampliSEQ
data, and National Genomics Infrastructure
Uppsala, Genome Center, and UPPMAX for
providing assistance in massive parallel
sequencing and computational infrastructure. This
work is supported by grants from The Cancer
Research Funds of Radiumhemmet (174153, JH),
the Swedish Cancer Society (CAN 2017-733, JH),
Knut and Alice Wallenberg foundation (2013-
0093, JH [coapplicant]), Torsten and Ragnar
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Clinical samples were collected as
formalin-fixed, paraffin-embedded
from pathology archives at Kar-
olinska University Hospital (Stock-
holm, Sweden), fresh fine needle
aspirates (for establishing short-term
cell culture), or core biopsies in
cell culture medium or RNAlater
from 41 patients with cutaneous
malignant melanoma with stage IV
disease obtained before start of
treatment with MAPK pathway in-
hibitor (BRAF inhibitor alone or in
combination with MEK inhibitor) or
immune checkpoint inhibitor or dur-
ing treatment and/or at progression
of disease. An additional 10 stage III/
IV formalin-fixed, paraffin-embedded
samples (treatment unknown) were
also collected (Supplementary Table
S2). Tissue microarray was pur-
chased from US Biomax (Rockville,
MD) (ME 1002A), including primary
cutaneous malignant melanoma tu-
mors (stage IeIV) and normal skin.
Data from The Cancer Genome Atlas
was used to perform copy number
variation, mRNA expression, and
survival analyses.Cell culture
A375VR4, a BRAFV600E mutated
BRAF inhibitor (vemurafenib)eresistant
cell line was derived in-house from
A375 ATCC (Manassas, VA) (Azimi
et al., 2017). NRAS mutant SkMel2
(Q61R) was purchased from ATCC, and
the BRAF/NRAS wild-type cell line
ESTDAB105 was purchased from Euro-
pean Searchable Tumor Line Database
and Cell Bank. BRAF mutant cell lines
were cultured in minimal essential
medium, and NRAS mutant and BRAF/
NRAS wild-type cells were cultured in
RPMI-1640 according to manufac-
turer’s protocol. All cell lines were
confirmed to be mycoplasma free. For
all experiments on clinical patient ma-
terial, short-term derived cell lines pa-
tients with cutaneous malignant
melanoma (generated in-house origi-
nating from fine needle aspirates ob-
tained pre- or posttreatment, see
Supplementary Table S5) were
cultured in DMEM (Gibco, Waltham,
MA) with 10% fetal bovine serum.Journal of Investigative Dermatology (2021), VolumCell viability assay (CellTitre-3D)
Spheres were formed using the hanging
drop method as previously described
(Das et al., 2019). Spheres were treated
with different concentrations of
TH1579 (0.5, 1.0, and 2.0 mM) for 72
hours. During this period, live cell im-
aging was performed every third hour
by Incucyte (Sartorius, Göttingen, Ger-
many). Cell viability was measured us-
ing CellTiter 3D (Promega, Madison,
WI) solution according to manufac-
turer’s protocol followed by measure-
ment of luminescence by Tecan Spark
10M microplate reader (Tecan Trading
AG, Männedorf, Switzerland).
Small interfering RNA transfection
Patient-derived cells (130-PRE and 150-
PRE) were transfected with small inter-
fering RNA against control, MTH1,
PMS2, or both using Lipofectamine
2000 according to manufacturer’s pro-
tocol. For sequences of small interfering
RNA, see Supplementary Table S4.
Flow cytometry
Annexin V and propidium iodide
staining signals (Sigma-Aldrich Chemie
Gmbh, Munich, Germany) were
measured by flow cytometry (Novocyte
3000, San Diego, CA). A minimum of
7,000 events were measured using
polygonal gating to exclude debris and
analyzed using Novoexpress software
(ACEA Biosciences, San Diego, CA) to
determine induction of apoptosis.
Immunoblotting
Protein was isolated using premade
RIPA buffer (Santa Cruz Biotechnology,
Dallas, TX) and supplemented with
additional protease (Santa Cruz
Biotechnology) and phosphatase in-
hibitor cocktails (Sigma-Aldrich
Chemie Gmbh). Protein concentration
was measured using BCA (Thermo
Fisher Scientific, Waltham, MA), and
immunoblotting was performed as per
manufacturer’s guidelines. Membranes
were incubated overnight with primary
antibodies against MTH1 (1:1,000,
Novus Biologicals, Littleton, CO) and
PMS2 (1:1,000, Novus Biologicals),
followed by secondary antibody incu-
bation with anti-rabbit (1:1,000) or
anti-mouse (1:2,000) (Cell Signaling
Technology, Danvers, MA). Signal
detection was performed using Image
Quant LAS 4000 (GE Healthcare
Europe GmbH, Freiburg, Germany).e -Immunofluorescence
Immunofluorescence was performed on
tissue microarray and formalin-fixed,
paraffin-embedded samples as previ-
ously described on manufacturer’s
website (Novus Biologicals). Briefly,
sections were dehydrated and antigen
retrieval was performed using citrate
buffer. Sections were stained overnight
with anti-MTH1 (1:100, Novus Bi-
ologicals) or anti-PMS2 (1:100, BD
Biosciences, Allschwil, Switzerland),
washed, incubated with secondary an-
tibodies (1:200, rabbit Alexa Fluor 488
or mouse Alexa Fluor 594, Cell
Signaling Technology), mounted with
DAPI (Sigma-Aldrich), and visualized
and imaged using AxioImager M2
(Zeiss, Oberkochen, Germany). The
intensity (negative, low, moderate, or
high) of MTH1- and PMS2-positive tu-
mor cells was evaluated. Specimens
with low expression had the majority of
tumor cells with a staining intensity of
1, moderate when the majority of tumor
cells had a staining intensity of 2, and
high when the majority of tumor cells
had a staining intensity of 3.
The Cancer Genome Atlas data sets
The skin cutaneous melanoma dataset
from cBioPortal has been used to
analyze associations of MTH1 and
PMS2 to progression free survival and
overall survival (Cerami et al., 2012;
Gao et al., 2013).
RNA extraction and qPCR
RNAwas extracted from clinical samples
and qPCR was performed as previously
described (Das et al., 2019). Details for
primers used in this study can be found
in Supplementary Table S1.
Statistical analysis
All experiments were conducted in
triplicate, and results were presented as
mean  SD or mean  SEM as
mentioned in figure legends. All statis-
tical analyses were carried out using
GraphPad Prism version 7.0 and
version 8.0 (GraphPad Software, San
Diego, CA). To compare difference and
Spearman rank correlation between
two groups, Student’s t-test was
employed. To compare differences be-
tween multiple groups, one-way
ANOVA test was used. For comparing
patient survival data, Mantel-Cox log-
rank test was employed.
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With alterations in copy number
in MTH1 and PMS2 (n = 11)
(median surivival = 25 months)
without alterations in copy numbers
in MTH1 and PMS2 (n = 305)
(median survival = 55 months)
with alterations in copy number
in MTH1 and PMS2 (n = 14)
(median survival = 29.19 months)
without alterations in copy number
in MTH1 and PMS2 (n = 344)





























Supplementary Figure S1. Kaplan-Meier curves showing shorter disease-free and overall survival in patients with CMM with CNV alterations in MTH2 and
PMS2. CNV in MTH1 and PMS2 is associated with shorter disease-free survival (n ¼ 316, P ¼ 0.03) and overall survival (n ¼ 358, P ¼ 0.001). CMM, cutaneous




































































Supplementary Figure S2. TH1579 treatment reduces PMS2 and induces p-H2AX protein levels in CMM
cell lines. Quantification of WB (Figure 2b) showing fold change in PMS2 and p-H2AX normalized to
actin loading control on treatment with DMSO or 1 mM TH1579 for 24 hours (n ¼ 2). p-H2AX,
phosphorylated H2AX; WB, western blot.
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Supplementary Table S1. Primers Used for qPCR in this Study
Gene Gene # Source Sequence PCR Product Length (bp)
MTH1 4521 Merck Sigma-Aldrich 50-AGTTGGAGTGGGAAGAAC-30 154
MTH1 4521 Merck Sigma-Aldrich 50-CTCCTTCTTGCACTTTGC-30 —
PMS2 5395 Merck Sigma-Aldrich 50-GGGTAGAAGAAGAAAACTTCG-30 99
PMS2 5395 Merck Sigma-Aldrich 50-GAAAGCCAAAAGTTTCAACC-30 —
HPRT1 3521 Eurofins AG 50-GACACTGGCAAAACAATGCAGAC-30 93
HPRT1 3521 Eurofins AG 50-GGTCCTTTTCACCAGCAAGCT-30 —
HMBS 3145 Eurofins AG 50-ACAACCGGGTGGGGCAGA-30 111
HMBS 3145 Eurofins AG 50-CCACCAGATCCAAGATGTCCTG-30 —
Abbreviation: bp, base pair.
Supplementary Table S2. A Summary of the Evaluation of MTH1 and PMS2 Protein Expression in Primary CMM
(Stage IeIV) and Normal Skin in TMA (ME 1002a) and Additional 29 Stage III/IV Metastatic Samples Using
Immunofluorescence










A1/A2 IIB Primary Low ND ND
A3/A4 III Primary Moderate Moderate ND
A5/A6 IIB Primary Moderate Moderate ND
A7/A8 IIA Primary NE NE ND
A9/A10 IIB Primary Moderate Moderate ND
B1/B2 IA Primary ND Low ND
B3/B4 IIB Primary Moderate Moderate ND
B5/B6 IIB Primary Moderate Moderate ND
B7/B8 IIB Primary Low ND ND
B9/B10 IIB Primary Low Low ND
C1/C2 III Primary Moderate Few Moderate ND
C3/C4 IIB Primary High ND ND
C5/C6 IIB Primary Moderate Moderate ND
C7/C8 IIB Primary Low ND ND
C9/C10 IIB Primary NE NE ND
D1/D2 III Primary High Few High ND
D3/D4 IB Primary Low Low ND
D5/D6 IIB Primary NE NE ND
D7/D8 III Primary Moderate ND Low
D9/D10 IIB Primary ND Low ND
E1/E2 IIB Primary NE Ne ND
E3/E4 IIB Primary Low Low ND
E5/E6 IIB Primary Moderate Moderate ND
E7/E8 IIA Primary NE NE ND
E9/E10 IIB Primary NE NE ND
F1/F2 IIB Primary Low Low ND
F3/F4 IIB Primary Moderate Moderate ND
F5/F6 IV Primary High Few High Moderate
F7/F8 IB Primary Low Low ND
F9/F10 III Primary Moderate ND ND
G1/G2 IIB Primary NE NE ND
G3/G4 IIB Primary Moderate Moderate ND
G5/G6 IIB Primary Low Low ND
G7/G8 IIC Primary Moderate Moderate ND
G9/G10 IIB Primary Moderate Moderate ND
J1/I2 Cancer-adjacent skin
tissue
Normal Low Low ND
(continued )
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Supplementary Table S2. Continued










J3/J4 Normal skin Normal Low Low ND
J5/J6 Normal skin Normal Low Low ND
J7/J8 Normal skin Normal ND Low ND
J9/J10 Normal skin Normal ND Low ND
1 III Metastatic ND Moderate ND
2 III Metastatic NE NE NE
3 III Metastatic High ND ND
4 III Metastatic Moderate Moderate ND
5 III Metastatic High ND Low
6 IV Metastatic Moderate ND Moderate
7 IV Metastatic High High Low
8 IV Metastatic High High Low
9 IV Metastatic High ND Low















Moderate Moderate Moderate V NR 35
003-PRE (excision) IV
Metastatic
Moderate ND Low V NR 60
040-PRE (excision) IV
Metastatic
High moderate Low D þ T NR 70
026-PRE (excision) IV
Metastatic





Low Low ND V DC 224
023-PRE:2 (core) IV
Metastatic
Low Moderate Low V DC 224
023-PROG:2 (core) IV
Metastatic
High Low Moderate V DC 224
112-PRE (excision) IV
Metastatic
Low Low Low P DC 8471
065-PRE (excision) IV
Metastatic
Moderate Moderate ND N DC 1,1831
127-PRE IV
Metastatic
ND Low ND N DC 7081
113-PRE IV
Metastatic
Low ND Few low P DC 8201
109-PRE IV
Metastatic
Moderate Moderate High P þ E NR 49
058-PRE (excision) IV
Metastatic
Low Moderate Low N DC 196
058-PRE (core) IV
Metastatic
ND Low ND N DC 196
059-PRE (excision) IV
Metastatic
Few low Few low ND N DC 1,2281
066-PRE (core) IV
Metastatic
Moderate Low ND N NR 119
066-PROG (core) IV
Metastatic
Moderate Low High N NR 119
083-PRE (core) IV
Metastatic
ND Low ND N NR 91
083-PROG (core) IV
Metastatic
Moderate Low Low N NR 91
Abbreviations: CMM, cutaneous malignant melanoma; D, dabrafenib; E, epacadostat; N, nivolumab; ND, not detectable; NE, not evaluable; No, number; P,
pembrolizumab; PFS, progression free survival; PRE, pretreatment; PROG, progression; T, trametinib; TMA, tissue microarray; v, vemurafenib.
1Patients still responding to treatment.
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Supplementary Table S4. siRNA Sequences Used in this Study against MTH1 and PMS2
Sequence # Supplier Target Sequence
MTH1 #1 Dharmacon 50-GACGACAGCUACUGGUUUC-30
MTH1 #3 Dharmacon 50-CGACGACAGCUACUGGUUU-30
PMS2 #1 Dharmacon 50-UAAUGAAGCUGUUCUGAUA-30
PMS2 #2 Dharmacon 50-UCUAUGAGUUCUUUAGCUA-30
Supplementary Table S3. Table Summarizing the Evaluation of MTH1 and PMS2 Staining Using
Immunofluorescence
Sample MTH1 Nuclear Expression MTH1 Cytoplasmic Expression PMS2 Nuclear Expression
Normal skin (n ¼ 4) ND (n ¼ 2)
Low (n ¼ 2)
Low (n ¼ 4) ND (n ¼ 4)
Cancer-adjacent skin tissue (n ¼ 1) Low (n ¼ 1) Low (n ¼ 1) ND (n ¼ 1)
Stage I (n ¼ 3) ND (n ¼ 1)
Low (n ¼ 2)
Low (n ¼ 3) ND (n ¼ 3)
Stage II (n ¼ 19) ND (n ¼ 1)
Low (n ¼ 7)
Moderate (n ¼ 10)
High (n ¼ 1)
ND (n ¼ 4)
Low (n ¼ 5)
Moderate (n ¼ 10)
ND (n ¼ 19)
Stage III (n ¼ 9)
Primary (n ¼ 5)
Metastatic (n ¼ 4)
Moderate (n ¼ 4)
High (n ¼ 1)
ND (n ¼ 1)
Moderate (n ¼ 1)
High (n ¼ 2)
ND (n ¼ 2)
Moderate (n ¼ 2)
High (n ¼ 1)
ND (n ¼ 2)
Moderate (n ¼ 2)
ND (n ¼ 4)
Low (n ¼ 1)
ND (n ¼ 3)
Low (n ¼ 1)
Stage IV (n ¼ 22)
Primary (n ¼ 1)
Metastatic1 (n ¼ 21)
High
ND (n ¼ 3)
Low (n ¼ 6)
Moderate (n ¼ 7)
High (n ¼ 5)
High
ND (n ¼ 5)
Low (n ¼ 8)
Moderate (n ¼ 6)
High (n ¼ 2)
Moderate
ND (n ¼ 7)
Low (n ¼ 10)
Moderate (n ¼ 3)
High (n ¼ 1)
Abbreviation: ND, not detectable.
1Two pretreatment metastases from patient 023 and 058 were analyzed and the tumor with highest expression was included in Supplementary Table S2.
Both tumors showed ND or low expression of MTH1 and PMS2.
Supplementary Table S5. A Summary of Which Treatments Were Received by the Patients from Whom FNA
Samples Were Procured for Establishing Primary Cell Cultures and Clinical Outcome
Cell Lines (Spheroids) FNA Taken Before/during/after Treatment Treatment Response
121-PRE Before Pembrolizumab DC
130-PRE Before Nivolumab DC
150-PRE Before Nivolumab þ Ipilimumab DC
159-PRE Before Pembrolizumab DC
181-PRE During Nivolumab DC
172-PROG After Nivolumab NR
Abbreviations: DC, disease control; FNA, fine needle aspirate; NR, nonresponder; PRE, pretreatment; PROG, progression.
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